Samsung Biologics

PharmAbcine expands partnership with Samsung Biologics for PMC-403

Monday, September 21, 2020 - 1:00pm

DAEJEON, SouthKorea, Sept. 21, 2020 /PRNewswire/ --PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders.

Key Points: 
  • DAEJEON, SouthKorea, Sept. 21, 2020 /PRNewswire/ --PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders.
  • Samsung will provide the full scope of its CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support.
  • PharmAbcine is a clinical-stage biotech company developing fully human therapeutic antibodies to treat cancer and neovascular disease.
  • PharmAbcine is developing PMC-403 as a therapeutic drug for both non ocular and ocular pathological vessel related diseases.

Samsung Biologics signs development agreement with Panolos for solid tumor treatment

Thursday, September 17, 2020 - 1:43am

INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors.

Key Points: 
  • INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors.
  • Under this agreement, Samsung Biologics will provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing.
  • "We are extremely proud to be partnering with Panolos in bringing PB101 closer to market," said Dr. Tae Han Kim, CEO Samsung Biologics.
  • Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services.

Samsung Biologics to add fourth plant with growing demands

Tuesday, August 11, 2020 - 1:30am

INCHEON, South Korea, Aug. 10, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today held an online press conference to announce its plans to break ground for a fourth plant within this year.

Key Points: 
  • INCHEON, South Korea, Aug. 10, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today held an online press conference to announce its plans to break ground for a fourth plant within this year.
  • This is part of its long-term strategy to maximize its operational efficiency and scale up its development and manufacturing capabilities in response to growing biomanufacturing demands.
  • Samsung Biologics is taking an innovative approach in the design strategy of its new plant: by incorporating the unique advantages from Plant 1, 2, and 3, it will offer multi-scale manufacturing services to support the diversifying needs of new and existing clients.
  • Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services.